Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Epigenetic reprogramming of immune cells in injury, repair, and resolution
Katarzyna Placek, … , Joachim L. Schultze, Anna C. Aschenbrenner
Katarzyna Placek, … , Joachim L. Schultze, Anna C. Aschenbrenner
Published July 22, 2019
Citation Information: J Clin Invest. 2019;129(8):2994-3005. https://doi.org/10.1172/JCI124619.
View: Text | PDF
Review Series

Epigenetic reprogramming of immune cells in injury, repair, and resolution

  • Text
  • PDF
Abstract

Immune cells are pivotal in the reaction to injury, whereupon, under ideal conditions, repair and resolution phases restore homeostasis following initial acute inflammation. Immune cell activation and reprogramming require transcriptional changes that can only be initiated if epigenetic alterations occur. Recently, accelerated deciphering of epigenetic mechanisms has extended knowledge of epigenetic regulation, including long-distance chromatin remodeling, DNA methylation, posttranslational histone modifications, and involvement of small and long noncoding RNAs. Epigenetic changes have been linked to aspects of immune cell development, activation, and differentiation. Furthermore, genome-wide epigenetic landscapes have been established for some immune cells, including tissue-resident macrophages, and blood-derived cells including T cells. The epigenetic mechanisms underlying developmental steps from hematopoietic stem cells to fully differentiated immune cells led to development of epigenetic technologies and insights into general rules of epigenetic regulation. Compared with more advanced research areas, epigenetic reprogramming of immune cells in injury remains in its infancy. While the early epigenetic mechanisms supporting activation of the immune response to injury have been studied, less is known about resolution and repair phases and cell type–specific changes. We review prominent recent findings concerning injury-mediated epigenetic reprogramming, particularly in stroke and myocardial infarction. Lastly, we illustrate how single-cell technologies will be crucial to understanding epigenetic reprogramming in the complex sequential processes following injury.

Authors

Katarzyna Placek, Joachim L. Schultze, Anna C. Aschenbrenner

×

Figure 1

Immune cell activation during different phases upon tissue injury.

Options: View larger image (or click on image) Download as PowerPoint
Immune cell activation during different phases upon tissue injury.
Tissu...
Tissue-resident immune cells, particularly γδT cells or resident macrophages, recognize damaged cells upon injury, e.g., via the NKG2D receptor or TLRs, respectively. Activated tissue-resident cells secrete soluble factors that attract other immune cells, such as proinflammatory cytokines (TNF-α, IFN-γ, IL-6, or IL-1) together with growth factors (PDGF, VEGF, or IGF-1) that stimulate epithelial cell proliferation. CXCL8 released by tissue-resident cells in response to TLR activation attracts neutrophils, which enter the site of injury. Neutrophils produce antimicrobial molecules, cytokines, and growth factors such as VEGF-A, which recruits other inflammatory cells such as monocytes and stimulates angiogenesis and tissue cell proliferation. Recruited phagocytes clean damaged tissue debris by phagocytosis and secrete various cytokines, proteases, and growth factors promoting tissue repair. They first acquire proinflammatory function [classically activated, or M(IFN-γ), macrophages] and, when the pathogen is cleared, can be repolarized toward antiinflammatory tissue repair [alternatively activated, or M(IL-4), macrophages] in the presence of cytokines produced by type 2 immune T cells. M(IL-4) macrophages secrete arginase; the growth factors VEGF-A, PDGF, and IGF; and other molecules. In the resolution phase, regulatory T cells suppress immune response by secreting IL-10 and TGF-β. Further, lipid-derived specialized pro-resolving mediators actively promote inflammation cessation, resolution, and repair.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts